Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial (Q44525441)
scientific article published in February 2008
Language:
(P31) (Q13442814)
(P304) 200-207
(P407) (Q1860)
(P433) 2
(P478) 144
(P577) Friday, February 1, 2008
(P921) (Q42824440)
(Q194908)
(Q269829)
(Q79460)
(Q10355321)
(Q422248)
(P1433) (Q15749524)
(P1476) "Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial" (language: en)
(P2093) Alexa B Kimball
Kenneth B Gordon
Richard G Langley
Alan Menter
Elliot K Chartash
Joaquin Valdes
ABT-874 Psoriasis Study Investigators
other details
description scientific article published in February 2008

External Links